# EDGAR Filing Document

**Accession Number:** 0002035832
**File Stem:** 0001193125-26-158944
**Filing Date:** 2026-4
**Character Count:** 16998
**Document Hash:** 4953ba8d32cdd144bcfff706ea413e2c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-158944.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001193125-26-158944

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260415

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aktis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0002035832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852584233
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43047
- **FILM NUMBER:** 26867441

**BUSINESS ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 978-237-4380

**MAIL ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): April 15, 2026

## Aktis Oncology, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-43047** | **85-2584233** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 17 Drydock Avenue, Suite 17-401

#### Boston, Massachusetts 02210

#### (Address of principal executive offices) (Zip Code)

#### Registrant's telephone number, including area code: (617) 461-4023

#### N/A

#### (Former name, or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.0001<br> per share | AKTS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.**  |

---

*Appointment of Glenn Gormley to the Board of Directors* 

On April 15, 2026, the board of directors (the "Board") of Aktis Oncology, Inc. (the "Company") appointed Glenn Gormley, MD, PhD as a Class I director of the Company, effective immediately. Dr. Gormley shall hold office for a term expiring at the 2027 Annual Meeting of the Company's stockholders, which is the next stockholder meeting at which Class I directors will be elected. Concurrent with his appointment to the Board, Dr. Gormley was appointed to the newly created Science and Technology Committee of the Board (the "Science and Technology Committee") to serve as Co-Chairperson along with Ken Herrmann, MD, PhD, a current member of the Board.

Glenn Gormley, MD, PhD, age 72, previously served as Global Head of Research and Development and Senior Executive Officer for Daiichi Sankyo, Ltd., a global pharmaceuticals company, as well as the President and Executive Chairman of Daiichi Sankyo, Inc., its United States subsidiary, from 2009 until 2019. From 2019 to 2022 he served as Executive Chairman of Daiichi Sankyo, Inc. Dr. Gormley has also served on the board of directors of Healios k.k. (TSE: 4593), a Japanese clinical-stage biotechnology company, since May 2022. Prior to that, Dr. Gormley was the Chief Executive Officer of Gemin X Pharmaceuticals, Inc., an oncology company, from 2008 until 2009, Global Head of Clinical Development and Medical Affairs at Novartis from 2006 until 2008, and the Chief Medical Officer of AstraZeneca from 2000 until 2006. Dr. Gormley received his MD and PhD from the University of Chicago and a BS in Biochemistry from UCLA, as well as board certifications in Pediatrics from UCLA and Pediatric Endocrinology from New York University. The Company believes that Dr. Gormley's extensive leadership and clinical development experience in the pharmaceuticals industry qualifies him to serve on the Board.

In accordance with the Company's Non-Employee Director Compensation Policy (the "Policy"), as a non-employee director of the Company, Dr. Gormley is initially entitled to receive cash compensation in the amount of $45,000 per year for his service on the Board and $15,000 per year for his service as the Co-Chairperson of the Science and Technology Committee, in each case, prorated for the portion of the year on which he serves on the Board and the committees thereof. In addition, pursuant to the Policy, on April 15, 2026, Dr. Gormley was granted an option under the Company's 2026 Equity Incentive Plan (the "Plan") to purchase up to 37,866 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") at an exercise price equal to the closing price of the Common Stock on the Nasdaq Global Select Market as of April 15, 2026 (the "Option"). The Options shall vest in equal annual installments over three years from the date of the grant, subject to Dr. Gormley's continued service with the Company through each such vesting date.

The Company also entered into an indemnification agreement with Dr. Gormley in the same form as its standard form of indemnification agreement.

There are no family relationships between Dr. Gormley and any director or executive officer of the Company, and he was not selected by the Board to serve as a director pursuant to any arrangement or understanding with any person. Dr. Gormley has not engaged in any transaction that would be reportable as a related-party transaction under Item 404(a) of Regulation S-K.

*Resignations of Helen S. Kim and Oleg Nodelman from the Board of Directors* 

On April 15, 2026, each of Helen S. Kim and Oleg Nodelman notified the Board of their decision to resign from their respective positions as members of the Board and all committees thereof, effective as of May 20, 2026. Ms. Kim and Mr. Nodelman's resignations are not due to any disagreement with the Company relating to any of the Company's operations, policies or practices.

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD.**  |

---

On April 16, 2026, the Company issued a press release regarding the appointment of Dr. Gormley to the Board and the resignations of Ms. Kim and Mr. Nodelman, which is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

------

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1\* | [Press Release, dated April 16, 2026.](d110479dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

\* Furnished herewith

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AKTIS ONCOLOGY, INC.**  | **AKTIS ONCOLOGY, INC.**  |
| Date: April 16, 2026 | By: | /s/ Kyle D. Kuvalanka |
|  |  | Kyle D. Kuvalanka |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors** 

BOSTON – April 16, 2026 – Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors.

"We are delighted to welcome Glenn to our Board as we continue to make significant progress toward upcoming clinical and corporate milestones," said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology. "Glenn brings deep expertise in global biopharmaceutical leadership and oncology innovation, having guided several blockbuster medicines to approval. In particular, Glenn's instrumental role in leading the discovery and development of a new generation of optimized, novel antibody drug conjugate (ADC) formats, which created an inflection point in the ADC field, is highly relevant to our vision of broadening the impact of targeted radiopharmaceuticals to large patient populations in need of new treatment options."

"I am thrilled to work with the Aktis Board and leadership team as the Company continues to gain momentum in broadening the reach and unique benefits of targeted radiopharmaceuticals for patients," said Dr. Gormley. "I am impressed not only by Aktis' novel miniprotein radioconjugate platform, but also by its robust end-to-end supply chain to ensure reliability and scalability of product delivery, which I see as key differentiators for Aktis as a next-generation radiopharmaceuticals leader."

Dr. Gormley brings more than three decades of biopharmaceutical leadership across research and development, executive leadership, and board service. Most recently, Dr. Gormley served as Senior Executive Officer and Global Head of Research and Development at Daiichi Sankyo Co., Ltd., and as Executive Chairman and President of Daiichi Sankyo, Inc. In these roles, he led the global R&D strategy and oversaw the development of a broad and diversified pipeline, including the successful build-out of Daiichi Sankyo's ADC platform. Prior to Daiichi Sankyo, Dr. Gormley held senior leadership positions at several global pharmaceutical companies. He served as Chief Medical Officer at AstraZeneca and as Global Head of Clinical Development and Medical Affairs at Novartis, where he led late-stage development and medical strategy across multiple programs. Earlier in his career, he held senior clinical development roles at Merck. Dr. Gormley holds an MD and a PhD from the University of Chicago and completed his training at UCLA and New York University leading to board certification in pediatrics and pediatric endocrinology.

Concurrent with Dr. Gormley's appointment to Aktis' Board of Directors, current Board members Helen Kim and Oleg Nodelman plan to step down from Aktis' Board of Directors, effective May 20, 2026.

"On behalf of the Board, I would like to thank Helen and Oleg for their commitment to Aktis from our earliest days as Series A investors and through our transition to a clinical-stage, publicly traded company," said Todd Foley, Co-Founder and Chairman of Aktis Oncology. "We are deeply grateful for their five years of service, which helped us establish a strong foundation for the Company and shape our ambitious strategy and vision for the future."

------

**About Aktis' miniprotein radioconjugate platform** 

Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis' therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end supply chain, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

**About Aktis Oncology** 

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis' most advanced pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis' second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis' proprietary pipeline. For more information, please visit <u>www.aktisoncology.com</u>.

**Forward-looking statements** 

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company's expectations about the timing of ongoing and planned clinical trials and regulatory filings, goals to develop and commercialize its product candidates, its liquidity and capital resources, and other statements identified by words such as "could," "expects," "intends," "may," "plans," "potential," "should," "will," "would," or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to the Company's limited operating history, its ability to obtain necessary funding, its ability to generate positive clinical trial results for its product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which the Company is subject, competitive pressures, its ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise these forward-looking statements.

------

**Media contact:** 

Melone Communications, LLC

Liz Melone

617-256-6622

<u>liz@melonecomm.com</u> 

**Investor contact:** 

Precision AQ

Alex Lobo

212-698-8802

<u>Alex.lobo@precisionaq.com</u>